MGC Pharmaceuticals Limited Expiry of Share Options (0694F)
July 13 2021 - 5:52AM
UK Regulatory
TIDMMXC
RNS Number : 0694F
MGC Pharmaceuticals Limited
13 July 2021
Expiry of Share Options and Appendix 3H
13 July 2021
ASX, LSE Code: MXC
MGC Pharmaceuticals Ltd (ASX: MXC, 'MGC Pharma' or 'the
Company') wishes to advise that 10,000,000 Share Options on issue
expired on 30 June 2021.
Further information can be found here
-Ends-
Authorised for release by David Lim, Company Secretary, for
further information, please contact:
MGC Pharmaceuticals Ltd PR/IR Advisors - Media & Capital
Roby Zomer Partners
CEO & Managing Director Rod Hinchcliffe (IR) +61 412
+61 8 6382 3390 277 377
info@mgcpharma.com.au Rod.Hinchcliffe@mcpartners.com.au
UK Broker - Turner Pope UK PR Advisors - Tavistock
Andy Thacker Charles Vivian +44 207 920
Andy.Thacker@TurnerPope.com 3150
Zoe Alexander +44 20 3657 Charles.Vivian@tavistock.co.uk
0050 Tim Pearson +44 7983 118 502
Zoe.Alexander@TurnerPope.com Tim.Pearson@tavistock.co.uk
About MGC Pharma
MGC Pharmaceuticals Ltd (LSE: MXC, ASX: MXC) is a European based
bio-pharma company developing and supplying affordable standardised
phytocannabinoid derived medicines to patients globally. The
Company's founders were key figures in the global medical cannabis
industry and the core business strategy is to develop and supply
high quality phytocannabinoid derived medicines for the growing
demand in the medical markets in Europe, North America and
Australasia. MGC Pharma has a robust product offering targeting two
widespread medical conditions - epilepsy and dementia - and has
further products in the development pipeline.
Employing its 'Nature to Medicine' strategy, MGC Pharma has
partnered with renowned institutions and academia to optimise
cultivation and the development of targeted phytocannabinoid
derived medicines products prior to production in the Company's
EU-GMP Certified manufacturing facility.
MGC Pharma has a number of research collaborations with world
renowned academic institutions, and including recent research
highlighting the positive impact of using specific phytocannabinoid
formulations developed by MGC Pharma in the treatment of
glioblastoma, the most aggressive and so far therapeutically
resistant primary brain tumour.
MGC Pharma has a growing patient base in Australia, the UK,
Brazil and Ireland and has a global distribution footprint via an
extensive network of commercial partners meaning that it is poised
to supply the global market.
Follow us through our social media channels :
Twitter: @MGC_Pharma
Facebook: @mgcpharmaceuticals
LinkedIn: MGC Pharmaceuticals Ltd.
Instagram: @mgc_pharma
This information is provided by RNS, the news service of the
London Stock Exchange. RNS is approved by the Financial Conduct
Authority to act as a Primary Information Provider in the United
Kingdom. Terms and conditions relating to the use and distribution
of this information may apply. For further information, please
contact rns@lseg.com or visit www.rns.com.
RNS may use your IP address to confirm compliance with the terms
and conditions, to analyse how you engage with the information
contained in this communication, and to share such analysis on an
anonymised basis with others as part of our commercial services.
For further information about how RNS and the London Stock Exchange
use the personal data you provide us, please see our Privacy
Policy.
END
MSCFIFEADLIVLIL
(END) Dow Jones Newswires
July 13, 2021 05:52 ET (09:52 GMT)
Mgc Pharmaceuticals (LSE:MXC)
Historical Stock Chart
From Jul 2024 to Aug 2024
Mgc Pharmaceuticals (LSE:MXC)
Historical Stock Chart
From Aug 2023 to Aug 2024